EpiPen's price has ballooned about 400% since 2008, rising from about a $100 list price to $500 today. The EpiPen is one of the most important life-saving medical innovations for people with severe food allergies—which affect as many as 15 million Americans and 1 in 13 children in the United States. But its price has exploded over the last decade despite few upgrades to the product itself. The product's lack of competitors is likely a significant driver of the costs. [...] [The] EpiPen enjoys a near-monopoly on the market with annual sales of more than $1.3 billion and nearly 90% U.S. market share.
(Score: 0) by Anonymous Coward on Tuesday August 23 2016, @08:31PM
estimates of drug development costs are around US$1.3 billion to US$1.7 billion.
Researchers would love to work together, but it is a question of resources. I would be happy if the US government or a non-profit would dump that kind of money into developing drugs without patents.
I'm also not convinced that fear of patent infringement is what is holding any of this back. If you mean incremental changes on small molecule drugs, then that already happens in pre-clinical development otherwise the abysmally low clinical trial success rate would be even lower. If you mean patents are interfering with academic research, then you are way off.
http://m.ctj.sagepub.com/content/early/2016/02/06/1740774515625964.full [sagepub.com]